Genomate Health joins CancerX to empower oncologists with cutting-edge digital innovation in the battle against cancer
Press release: Cambridge, MA, 3 June 2023
Genomate Health and CancerX have recently joined forces to advance the fight against cancer by unleashing the power of digital innovation. The aim of this public-private partnership is to unite multiple stakeholders and innovators to create a future that's free of the burden of cancer.
Through this partnership, Genomate Health and CancerX will work together to develop and implement cutting-edge digital solutions that empower oncologists to provide more personalized and effective cancer treatments. By leveraging the latest advancements in artificial intelligence and precision oncology, the partnership will help oncologists to make better, data-driven decisions about cancer treatment options.
With Genomate's powerful computational tool in precision oncology and CancerX's mission to bring together the brightest minds in the field, the partnership will accelerate the pace of innovation in cancer research and treatment. By combining their expertise, Genomate and CancerX aim to improve cancer outcomes and bring us one step closer to a future without cancer.
This partnership is a significant milestone in the fight against cancer, and it is expected to have a profound impact on the lives of cancer patients and their families around the world. By empowering oncologists with cutting-edge digital innovation, Genomate and CancerX are committed to transforming cancer care and creating a brighter future for all.
Very excited to join this much-needed initiative. This is a great partnership, as CancerX and Genomate Health are perfectly aligned in the overarching mission to improve treatment outcomes for all cancer patients. I truly believe this is an attainable goal - with AI on our side, we can improve, automate, and democratize precision oncology to make it better, faster, and more affordable for all cancer patients. - Istvan Petak, physician-scientist, Founder & CEO of Genomate Health
About Genomate Health: Genomate Health Inc. is a digital health company (based in Cambridge, MA) that develops AI-powered computational tools for personalized medicine. Its main focus is assisting physicians in making optimal personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases.
Its flagship product, Genomate® MTC (Molecular Treatment Calculator), is a powerful computational (open box AI) tool aiming to optimize treatment decision-making in precision oncology by automated data compilation, evaluation, and synthesis in a knowledge model allowing standardized, personalized treatment decisions based on the totality of available molecular information. The company’s goal is to make this solution globally available to cancer patients and their oncologists in 2023. For more information, visit www.genomate.health.
About CancerX: Announced by the White House Cancer Moonshot in February, CancerX is a public-private partnership to boost innovation in the fight against cancer. Co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center, alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), it convenes the many diverse stakeholders needed to unleash the power of innovation to create a future that's free of cancer burden. To learn more or participate in CancerX's pre-competitive, evidence-generating efforts; Accelerator cohort, or demonstration projects, visit www.cancerx.health.
.png)
